51555-87-4

中文名稱 D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷

英文名稱 THIODIGALACTOSIDE

CAS 51555-87-4

分子式 C12H22O10S

分子量 358.36

MOL 文件 51555-87-4.mol

更新日期 2025/04/17 10:05:56

51555-87-4 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷價(jià)格(試劑級(jí)) 常見(jiàn)問(wèn)題列表

基本信息

中文別名

硫代半乳糖苷
N4苯甲?；?'-O-DMT-5-甲基
D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷
(D-GALACTOPYRANOSYL)-B-D-THIOGALACTOPYRANOSIDE 硫代二半乳糖苷

英文別名

TDG
THIODIGALACTOSIDE
Galactosyl 1-thiogalactoside
D-Galactopyranosyl-b-D-thiogalactopyranoside
d-galactopyranosyl-β-d-thiogalactopyranoside
D-GALACTOPYRANOSYL BETA-D-THIOGALACTOPYRANOSIDE
D-Galactopyranosyl-β-D-thiogalactopyranoside ,98%
β-D-Galactopyranoside, β-D-galactopyranosyl 1-thio-

所屬類別

生物化工：抑制劑

物理化學(xué)性質(zhì)

熔點(diǎn)>225°C (dec.)

儲(chǔ)存條件−20°C

溶解度二甲基亞砜（微溶）

形態(tài)固體

顏色白色

水溶解性H2O: 2mg/mL, clear

InChIInChI=1/C12H22O10S/c13-1-3-5(15)7(17)9(19)11(21-3)23-12-10(20)8(18)6(16)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11+,12?/s3

InChIKeySYKYBMOFPMXDRQ-YSLNCGCNNA-N

SMILESC1([C@H](O)[C@H]([C@@H](O)[C@@H](CO)O1)O)S[C@H]1[C@H](O)[C@H]([C@@H](O)[C@@H](CO)O1)O |&1:1,3,4,6,12,13,15,16,18,r|

安全數(shù)據(jù)

WGK Germany3

海關(guān)編碼29389090

存儲(chǔ)類別11 - Combustible Solids

圖譜信息

D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷(51555-87-4)核磁圖(¹HNMR)

D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱	CAS號(hào)	包裝	價(jià)格
2026/06/05	HY-130208	D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷 Thiodigalactoside	51555-87-4	5 mg	253元
2026/06/05	HY-130208	D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷 Thiodigalactoside	51555-87-4	10mM * 1mLin Water	278元
2026/06/05	HY-130208	D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷 Thiodigalactoside	51555-87-4	10 mg	380元

常見(jiàn)問(wèn)題列表

生物活性

Thiodigalactoside (TDG) 是一種具有口服活性的，有效的半乳凝素 (GAL) 抑制劑，對(duì)于 GAL-1 和 GAL-3 的 Kd 值分別為 24 μM，49 μM。Thiodigalactoside 是一種不可代謝的二糖，具有抗炎和抗癌活性。Thiodigalactoside 可顯著降低飲食誘發(fā)的肥胖大鼠的體重增加。

靶點(diǎn)

Kd: 24 μM (GAL1) and 49 μM (GAL3)

體外研究

Thiodigalactoside (TDG; 250 and 500?μM) exhibits dose-dependent reduction of fat accumulation based on triglyceride (TG) content and Oil Red O (ORO) staining.

體內(nèi)研究

Thiodigalactoside (TDG; 5?mg/kg; IP; once per week for 5 weeks) results in dramatic inhibition of HFD-induced body weight gain.
Thiodigalactoside (5?mg/kg; oral; daily or weekly for 5 weeks) gave less reduction in body weight gain compare with i.p..

Animal Model:	Five-week-old Sprague-Dawley (SD) male rats
Dosage:	5?mg/kg
Administration:	IP; once per week for 5 weeks
Result:	Resulted in dramatic inhibition of HFD-induced body weight gain by inhibiting adipogenesis and lipogensis as well as by increasing expression of the proteins associated with thermogenesis and energy expenditure.